A detailed history of Daiwa Securities Group Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 8,813 shares of IOVA stock, worth $92,183. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,813
Previous 1,032 753.97%
Holding current value
$92,183
Previous $15,000 373.33%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$7.78 - $14.19 $60,536 - $110,412
7,781 Added 753.97%
8,813 $71,000
Q1 2024

May 02, 2024

BUY
$7.59 - $17.47 $1,176 - $2,707
155 Added 17.67%
1,032 $15,000
Q1 2023

May 02, 2023

BUY
$5.53 - $8.22 $1,609 - $2,392
291 Added 49.66%
877 $5,000
Q2 2022

Aug 09, 2022

BUY
$6.38 - $18.33 $816 - $2,346
128 Added 27.95%
586 $6,000
Q4 2021

Feb 03, 2022

SELL
$16.55 - $27.63 $1,208 - $2,016
-73 Reduced 13.75%
458 $9,000
Q3 2021

Nov 05, 2021

BUY
$20.35 - $26.63 $4,884 - $6,391
240 Added 82.47%
531 $13,000
Q1 2021

May 03, 2021

BUY
$28.67 - $52.59 $430 - $788
15 Added 5.43%
291 $9,000
Q4 2020

Feb 04, 2021

SELL
$28.04 - $50.26 $15,225 - $27,291
-543 Reduced 66.3%
276 $13,000
Q3 2020

Nov 02, 2020

BUY
$27.75 - $36.3 $2,969 - $3,884
107 Added 15.03%
819 $27,000
Q4 2019

Jan 31, 2020

SELL
$17.95 - $29.41 $1,310 - $2,146
-73 Reduced 9.3%
712 $20,000
Q1 2019

Apr 26, 2019

BUY
$8.41 - $11.26 $3,229 - $4,323
384 Added 95.76%
785 $7,000
Q1 2018

May 02, 2018

BUY
$8.1 - $19.5 $3,248 - $7,819
401 New
401 $7,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.65B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.